He-long Zhang

1 Xinsi Road
Xi'an, 710038, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.

Journal: Journal of cancer research and clinical oncology
Published: April 14, 2023

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.

Journal: Future oncology (London, England)
Published: January 19, 2023

A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions.

A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions.

Journal: Cancer chemotherapy and pharmacology
Published: September 14, 2022

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma.

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma.

Journal: Frontiers in oncology
Published: February 21, 2022

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.

Journal: Targeted oncology
Published: January 27, 2021

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.

Journal: Frontiers in oncology
Published: January 21, 2020

Effect of CUL4A on the metastatic potential of lung adenocarcinoma to the bone.

Effect of CUL4A on the metastatic potential of lung adenocarcinoma to the bone.

Journal: Oncology reports
Published: June 28, 2019

The role of GDF15 in bone metastasis of lung adenocarcinoma cells.

The role of GDF15 in bone metastasis of lung adenocarcinoma cells.

Journal: Oncology reports
Published: July 30, 2018

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Journal: Translational lung cancer research
Published: July 28, 2018

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.

Journal: Cancer letters
Published: April 10, 2017

Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.

Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.

Journal: Cancer
Published: February 20, 2017

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.

Journal: ESMO open
Published: February 01, 2017
Showing 1-12 of 19

Last Updated: 09/26/2026